Inserting Long Acting Reversible Contraception (LARC) Immediately After Childbirth
Date: January 2016
About this Independent Study
Expiration Date: This activity was originally released on September 30, 2014 and is available for continuing education credit until April 1, 2020. Reviewed/updated June 26, 2019.
The 2013 Centers for Disease Control and Prevention’s (CDC) U.S. Selected Practice Recommendations for Contraceptive Use recommends offering intrauterine and subdermal contraception immediately after childbirth as part of a full range of contraceptive options. There is growing evidence that inserting LARC devices soon after delivery poses no increased health or safety risk and increases method continuation rates. Despite evidence of safety and efficacy, relatively few providers offer this option.
This course addresses the indications for insertion of intrauterine and subdermal contraception immediately following childbirth. Participants will view a video demonstration showcasing correct postpartum IUD (PPIUD) insertion technique. They will learn best practices for insertion and managing complications. An optional video teaches participants how to construct a model for practicing the technique in their own health care setting. This training offers participants knowledge and resources to enable them to provide an important option for their clients.
This course is designed for clinical providers, registered nurses, counselors, and administrative staff who work in either prenatal care or labor and delivery settings. They will learn about counseling messages, clinical systems and evidence-based practices for offering LARC methods in the immediate postpartum period.
Participants should have previous knowledge about LARC insertion in patients who are not postpartum. Licensed providers should have previous knowledge and experience with IUD insertion to learn the specific techniques for postpartum insertion.
By the end of this course, the participants will be able to:
- Identify appropriate candidates for immediate postpartum long acting reversible contraceptive (LARC) insertion.
- Describe best practices for LARC insertion in the immediate postpartum period.
- Describe appropriate management of potential complications occurring after postpartum IUD insertion.
- Identify resources to assist them in furthering their ability to manage postpartum LARC insertions.
Sarah Prager, MD, MAS
University of Washington
Dr. Prager is currently an Associate Professor at the University of Washington in the Department of Obstetrics and Gynecology. She is the Family Planning Fellowship director and the associate director of the Ryan Training Program for family planning. She splits her time between clinical work, teaching and research. She mentors residents and fellows through family planning related projects. Her particular areas of research interest are post abortion contraception, IUDs and miscarriage management. She has also developed a number of training curricula for miscarriage management, office-based procedures, high-risk contraception and resident family planning training. Dr. Prager has been a family planning specialist for 9 years.
Registration & Fees
The independent study is FREE of charge. It requires a brief registration process and participants can request a Certificate of Participation at no charge upon completion of an online evaluation.
A $15 fee is charged for each Continuing Nursing Education (CNE) and Continuing Medical Education (CME) certificate.
Continuing Education (CE)
Participants who wish to receive a CNE or CME certificate, must
- Attend the entire CE activity
- Complete the online evaluation
- Submit an online CE Request
Cardea Services is an approved provider of continuing nursing education by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.
Upon successful completion of this educational activity 1.6 contact hours (including 1.5 hours of pharmacology) will be awarded.
Cardea is accredited by the California Medical Association for issuing AMA PRA Category 1 Credit(s)™ for physicians.
Cardea designates this enduring material for a maximum of 1.6 AMA PRA Category 1 Credit(s)™. Physicians should claim credit commensurate with the extent of their participation in the activity.
Non-Endorsement of Products
Approved provider status does not imply endorsement by Cardea or the Washington State Department of Health of any products displayed in conjunction with this activity.
Funding is provided by the Washington State Department of Health, Prevention and Community Health Division.
The update in 2016 was funded by Allergan